Versão BETA

Acesso livre
Acesso livre

Aprovação do FDA para medicamento contra o Alzheimer gera controvérsia entre médicos.

9 Jun, 2021 | 09:49h

Comunicado de imprensa: FDA Grants Accelerated Approval for Alzheimer’s Drug – U.S. Food & Drug Administration

Comentários: ICER Issues Statement on the FDA’s Approval of Aducanumab for Alzheimer’s Disease – Institute for Clinical and Economic Review E Landmark Alzheimer’s Drug Approval Confounds Research Community – Nature E FDA approves Alzheimer’s drug from Biogen, against experts’ advice – NBC News E F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works – The New York Times (alguns artigos gratuitos por mês) E Alzheimer’s drug approved despite doubts about effectiveness – Science (alguns artigos gratuitos por mês) E The FDA Has Approved A New Alzheimer’s Drug — Here’s Why That’s Controversial – NPR E Opinion: Bad medicine: aducanumab is a lackluster drug with a high price tag – STAT


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.